The tariff rate on pharmaceuticals imported from Switzerland and Liechtenstein to the United States is in line with Trump’s trade agreement in late July with the EU.
The Australia-headquartered biopharma company will expand its footprint in the United States. Since 2018, it has invested over $3 billion in U.S. operations.
